Aerie Pharmaceuticals, Inc. (AERI) Formed a Multiple Top Pattern, Could Be One of The Best Performers Soon

December 20, 2017 - By Hazel Jackson

Investors sentiment increased to 1.17 in Q2 2017. Its up 0.21, from 0.96 in 2017Q1. It improved, as 21 investors sold Aerie Pharmaceuticals, Inc. shares while 48 reduced holdings. 33 funds opened positions while 48 raised stakes. 31.61 million shares or 3.55% more from 30.53 million shares in 2017Q1 were reported.
Wellington Mngmt Grp Limited Liability Partnership invested 0.04% of its portfolio in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Atika Capital Limited Liability Co holds 1.2% or 65,000 shares in its portfolio. Baker Bros Advsrs Limited Partnership holds 0.14% of its portfolio in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) for 299,356 shares. Quantitative Investment Mngmt Lc accumulated 71,200 shares. Creative Planning holds 0% of its portfolio in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) for 3,600 shares. 61,959 are held by Granite Point Cap Mgmt Limited Partnership. Eam Investors Lc stated it has 72,930 shares or 0.63% of all its holdings. Next Century Growth Limited Liability has invested 0.7% of its portfolio in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). 2.16M were reported by Vanguard Grp Inc. Morgan Stanley reported 0% of its portfolio in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Comml Bank Of Montreal Can holds 0% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) or 513 shares. Tower Research Ltd Com (Trc) invested in 0% or 237 shares. 34,134 were accumulated by Retail Bank Of America De. California Public Employees Retirement Systems reported 0% of its portfolio in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Envestnet Asset Mngmt reported 414 shares.

The stock of Aerie Pharmaceuticals, Inc. (AERI) shows a multiple tops pattern with $60.00 target or 3.00 % above today’s $58.25 share price. The 6 months chart pattern indicates low risk for the $2.14 billion company. It was reported on Dec, 20 by Finviz.com. If the $60.00 price target is reached, the company will be worth $64.14M more.
Multiple tops are chart patterns with decent performance in a bull market. The failure rate is higher but the average decline is reasonable. Back-tests of such patterns show that the break even failure rate is 10%, the average rise: 19%, the throwback rate: 61% and the percentage of stocks meeting their price targets: 40%.

The stock decreased 0.09% or $0.05 during the last trading session, reaching $58.25. About 1.16M shares traded or 90.82% up from the average. Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) has risen 180.20% since December 20, 2016 and is uptrending. It has outperformed by 163.50% the S&P500.

Analysts await Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) to report earnings on March, 6. They expect $-1.44 EPS, down 65.52 % or $0.57 from last year’s $-0.87 per share. After $-0.89 actual EPS reported by Aerie Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 61.80 % negative EPS growth.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Ratings Coverage

Among 14 analysts covering Aerie Pharmaceuticals (NASDAQ:AERI), 14 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aerie Pharmaceuticals has $10000 highest and $30 lowest target. $69.83’s average target is 19.88% above currents $58.25 stock price. Aerie Pharmaceuticals had 43 analyst reports since August 7, 2015 according to SRatingsIntel. Cowen & Co maintained the stock with “Buy” rating in Thursday, November 9 report. Cantor Fitzgerald maintained Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) on Thursday, November 16 with “Buy” rating. Stifel Nicolaus maintained Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) on Thursday, July 27 with “Buy” rating. The stock of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) earned “Buy” rating by H.C. Wainwright on Thursday, July 20. RBC Capital Markets maintained it with “Outperform” rating and $55 target in Thursday, September 15 report. The stock of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) earned “Buy” rating by Cantor Fitzgerald on Thursday, July 20. The stock has “Buy” rating by Canaccord Genuity on Wednesday, September 20. The stock of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) has “Buy” rating given on Monday, October 16 by Canaccord Genuity. Stifel Nicolaus maintained the stock with “Buy” rating in Thursday, October 6 report. The company was initiated on Tuesday, November 1 by Aegis Capital.

More notable recent Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) news were published by: Zacks.com which released: “Falling Earnings Estimates Signal Weakness Ahead for Aerie Pharmaceuticals …” on December 07, 2017, also Nasdaq.com with their article: “Falling Earnings Estimates Signal Weakness Ahead for Aerie Pharmaceuticals (AERI)” published on December 07, 2017, Reuters.com published: “Aerie’s glaucoma treatment gets early FDA approval” on December 18, 2017. More interesting news about Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) were released by: Fool.com and their article: “Aerie Pharmaceuticals Nabs FDA OK for Glaucoma Drug” published on December 20, 2017 as well as Marketwatch.com‘s news article titled: “Aerie Pharma eye drug Rhopressa approved by FDA” with publication date: December 18, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.